Slide background

Actemra Lawsuit – Rheumatoid Arthritis (RA) Drug

Actemra® Facts: Failure to Warn

Stat News presents a compelling piece on the absence of warnings in the Actemra label regarding the increased risk of heart attack, stroke, interstitial lung failure, acute pancreatitis, and death.

Stat News analyzed Food & Drug Administration (FDA) data in an attempt to determine the adequacy of the Actemra® label. It found 1,128 deaths in Actemra users have been reported to the FDA since the launch of the product. It also found an unusually large number of serious adverse events that did not appear.

It also found an unusually large number of serious adverse events that did not appear in the drug’s label.

For instance, it found:

Adverse Event

Heart attack Stroke Heart Failure Interstitial Lung Disease Pancreatitis
Labeled? No No No No No
Cases 410 359 224 222 132

Adverse Event

Labeled? Cases
Heart attack No 410
Stroke No 359
Heart Failure No 224
Interstitial Lung Disease No 222
Pancreatitis No 132

Other RA drugs such as Remicade® and Humira® warn of the risk of heart attack, stroke, heart failure, interstitial lung disease and pancreatitis. On the other hand, the Actemra® label is silent regarding these life threatening and altering medical conditions.

Approximately 1.5 million Americans have rheumatoid arthritis (RA). RA is an autoimmune disorder where the body’s immune system begins to attack and destroy the body’s joints. RA is a painful and disabling disease.

When Actemra® was marketed in 2010 it was not associated with heart attack, stroke, heart failure or life threatening lung disorders. However, the approval was based solely on short term studies with the hope that long term studies would establish the safety and effectiveness of Actemra.

Taken intravenously or by injection, Actemra® has been used by over 760,000 patients. Actemra generated over 1.7 billion in revenue in 2016 for its manufacturer Genetech a division of the Roche Group.

Do Not Stop Using Your Prescription Medicine With-Out First Consulting Your Physician.

Why select the James Esparza Law Firm?

Our clients select us because they are looking for a law firm that is dedicated to them and their case. Our firm is only involved in product liability cases with an emphasis of on pharmaceutical litigation.

If you are looking for personal attention for your Actemra® case call James Esparza at 1-800-745-4050.

Law done differently!

Personal Attention: We offer each client personal attention and the respect they deserve. If you select us to represent you, we will work hard and do the best we can for you. We make no promises other than the one of hard work for you.

Only a few – We are exclusive!

Many firms accept as many clients as possible. We do not. We select only a few. Some say we are exclusive. We say is just how legal services should be delivered to the client. In mass tort litigation, such as the testosterone litigation, you really need individual attention because the cases are extremely complicated. Ask your-self, how a law firm can give my case the time it deserves when they have accepted thousands of similar cases. Don’t accept less. Be one of the few. You are not a commodity.

Choosing a lawyer is difficult and clients have to make decisions with imperfect information. In our experience the best safety-net for a client is to talk to us. Our conversations are informative, valuable and meaningful. Our conversations with our clients serve as the basis of a lasting working relationship.

How we get paid

We work on a contingent fee just like Abraham Lincoln did. This means we have to be successful for you to get paid.


Have you got a Question?

Personal service is the guiding principle of the James Esparza Law Firm. From the time a client calls we are working hard to create a lasting relationship. We don’t accept cases – we accept clients.
299 South Main Street, 13th Floor
Salt Lake City, UT 84111
Toll Free:800-745-4050